Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Jahr

2012

Autoren

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Ziemssen T, Compston DA; CARE-MS II investigators.

Verlag

Lancet. 2012 Nov 24;380(9856):1829-39.

Link

https://doi.org/10.1016/s0140-6736(12)61768-1

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study